GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT04292912
- Locations
- 🇳🇿
GSK Investigational Site, Christchurch, New Zealand
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT04276233
- Locations
- 🇮🇳
GSK Investigational Site, Pune, India
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 494
- Registration Number
- NCT04246047
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
Phase 3
Completed
- Conditions
- Urinary Tract Infections
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1606
- Registration Number
- NCT04187144
- Locations
- 🇵🇱
GSK Investigational Site, Warszawa, Poland
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT04177823
- Locations
- 🇨🇳
GSK Investigational Site, Beijing, China
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Phase 2
Active, not recruiting
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Combination Product: Belimumab
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT04179032
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
Phase 3
Active, not recruiting
- Conditions
- Herpes Zoster
- Interventions
- Biological: HZ/su vaccine (GSK1437173A)
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT04176939
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Linerixibat Long-term Safety, and Tolerability Study
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 245
- Registration Number
- NCT04167358
- Locations
- 🇬🇧
GSK Investigational Site, Surrey, United Kingdom
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 3
Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: Pom/dex (Pomalidomide plus low dose Dexamethasone)
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 325
- Registration Number
- NCT04162210
- Locations
- 🇬🇧
GSK Investigational Site, Plymouth, United Kingdom
Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT04151225
© Copyright 2025. All Rights Reserved by MedPath